Proton International, LLC

Exciting day for healthcare in Connecticut! Today, we broke ground on the Connecticut Proton Therapy Center in Wallingford—a partnership between Yale New Haven Health and Hartford HealthCare, in collaboration with Proton International, LLC , Yale Medicine, and Radiation Oncology Associates, PA. This 25,000-square-foot facility will offer advanced proton therapy, a cutting-edge cancer treatment that uses a targeted proton beam rather than traditional X-rays. With completion set for mid-2026 and the first patients expected by December 2026, this center will be a game-changer for cancer care in the region. We’re proud to lead the way in delivering patient-centric, breakthrough treatments that will improve outcomes and save lives.

"It hardly seems possible, but today we mark one year since the opening of the Proton Center of Arkansas, a collaboration of the UAMS - University of Arkansas for Medical Sciences, Baptist Health, Arkansas Children's and Proton International, LLC. It was a proud day for us and for healthcare in Arkansas as we joined a small, elite group of states that offer this groundbreaking therapy for children and adults with cancer. "Thank you to our partners, employees and everyone who helped make the Proton Center of Arkansas a reality for cancer patients in Arkansas," Cam Patterson, M.D., MBA, UAMS Chancellor. ProtonCenterofArkansas.com #protontherapy #Arkansas

It’s hard to believe that the Proton Center of Arkansas has already been open for a year. Dr. Bowers, my grandfather, was a proud member of the Arkansas medical establishment, so it’s particularly rewarding for me to have our team serve the same community now. There are so many people to acknowledge on this anniversary, but I want to start with our key partners: Arkansas Children’s, Baptist Health, and UAMS. I’d like to personally thank UAMS’s Chief Clinical Officer Dr. Abuabdou, Center Administrator Megan Meckling, and PI’s Chief Medical Officer Dr. Snider for their continued commitment and leadership. ProtonCenterofArkansas.com │Appointments: 501-664-4568 The Winthrop P. Rockefeller Cancer Institute at UAMS UAMS - University of Arkansas for Medical Sciences Arkansas Children's Baptist Health IBA #ProtonTherapy #radiationtherapy #cancercare #cancertreatment #pediatriccancer #littlerockarkansas

I am thrilled to announce that Dr. J.W. Snider has accepted the position of Chief Medical Officer at Proton International. James W. (J.W.) Snider, III, M.D. is a radiation oncologist specializing in Proton and Photon/X-ray Radiation Therapies as well as the treatment of numerous malignancies including Head/Neck Cancer, Prostate Cancer, Sarcomas, Breast Cancer, Lung Cancer, and Spine malignancies. Prior to becoming Proton International’s (PI) Chief Medical Officer, Dr. Snider treated patients at the South Florida Proton Therapy Institute (SFPTI) and served as PI’s Corporate Medical Director. He also previously led the center in Birmingham, AL as the Medical Director of Proton International at the University of Alabama at Birmingham (UAB). For his education, Dr. Snider completed two bachelor's degrees at the University of Alabama before attending the Georgetown University School of Medicine. He performed his internship at Georgetown/INOVA Fairfax Hospital. Dr. Snider completed his residency training in Radiation Oncology at the University of Maryland Medical Center, serving as Chief Resident. Dr. Snider was also selected for and completed a Clinical/Research Proton Fellowship at the world-renowned Paul Scherrer Institute Center for Proton Therapy in Villigen, Switzerland – the birthplace of pencil beam scanning technology. He subsequently was on faculty at the University of Maryland as an Assistant Professor radiation oncologist. He then joined the University of Alabama at Birmingham radiation oncology team as an Associate Professor and the Associate Medical Director of Proton Therapy, followed by his roles for SFPTI and PI. Dr. Snider’s research has focused on Pencil Beam Scanning Proton Therapy, Stereotactic Radiotherapy, Spatially Fractionated Radiotherapy, Head/Neck Cancer, Sarcomas, Concurrent Thermoradiotherapy, Spine Tumors, Proton Therapy efficiency/workflow improvement, and unique treatment/device-development. Dr. Snider has published numerous peer-reviewed articles, has given countless national/international presentations, and has received many awards and honors for his service to the fields of radiation oncology and Proton Therapy. On an organizational level, Dr. Snider is an active member, serving on numerous boards and committees, for the Particle Therapy Co-Operative Group (PTCOG), PTCOG-NA, Radiosurgery Society, Chondrosarcoma Foundation, National Association for Proton Therapy, and the American Society for Radiation Oncology. Dr. Snider brings over a decade of clinical and leadership experience in Proton Therapy to the PI team. His expertise in leading, growing, and training developing centers augments PI's armamentarium vastly in ensuring the highest quality of evidence-based clinical care with careful attention to center efficiency, operational improvements, and practice unification/standardization. #Protontherapy #NAPT #PTCOG #RadiationOncology

?? Thrilled to share that IBA Proton Therapy has signed a contract with the #Connecticut Proton Therapy Center for the installation of a #ProteusONE compact proton therapy system, a collaboration between Yale New Haven Health, Hartford HealthCare and Proton International, LLC. The Connecticut Proton Therapy Center will be the first in the state, offering treatments by top physicians affiliated with Yale School of Medicine, the Smilow Cancer Hospital at Yale-New Haven, the Yale Cancer Center, which is a National Cancer Institute (NCI) Comprehensive Cancer Center, and the HARTFORD HEALTHCARE CANCER INST AT HOSP CENTRAL CT.? ?? Read the full press release here: https://lnkd.in/gQR_zGaj #HealthcareInnovation #ProtonTherapy #CancerCare #IBA

Innovations in Healthcare Payment Reform only at?#2024NPC??? Dive into the complex world of healthcare payments with leading experts from?Mayo Clinic,?MedAustron, &?Point32Health . Explore the world of?payment?reform and uncover the impact of research on payor policies, ROCR, gold carding and innovative Alternative?Payment?Methods. ?? Featuring an expert-packed panel of: Sameer Keole, Hug Eugen, Hemant H. ?? 2024 NATIONAL PROTON CONFERENCE ? April 6-9, 2024 ?? BOSTON, MA https://lnkd.in/gjsPVg_4 Why Attend? Ideal for healthcare professionals, policymakers, and anyone interested in the future of cancer treatments. Sign up today! #HealthcareInnovation?#PaymentReform

Southern Healthcare Transformed: NAPT visits Arkansas' first Proton Center! Our Executive Director, Jennifer Maggiore, recently was able to witness first hand cutting-edge IBA technology in action at Proton Center of Arkansas. This state-of-the-art center is expanding access to precise, targeted treatment for cancer patients of all ages. Truly an inspiring visit that underscores our industry's commitment to the latest in cancer care innovation! #ProtonTherapy #IBATechnology #CancerCareInnovation

As we say goodbye to 2023, I want to reflect on what an amazing year it’s been for Proton International London and share our plans for the new year. In 2023, we made significant achievements by expanding our services and improving the comprehensiveness and accessibility of our care to a more diverse range of patients. We added prostate and lung cancers to the list of cancers that can now be treated with proton beam therapy (PBT), expanded the indications for head & neck cancers, and made great progress in the field of neuro-oncology, extending the age range for patients seeking PBT for neurological tumours. Our collaboration with insurers has played a crucial role in making this advanced treatment more widely accessible, allowing us to expand our impact. Proton International London has made a significant impact globally, and it brings me great joy to share our expertise with people from around the world. Seeing the strength and resilience shown by our patients and their families has deepened our sense of purpose and observing the positive impact of our treatments on children fills our team with motivation for 2024. In the new year, we will be introducing new indications, broadening our capabilities, and reaching important milestones in PBT. We are also eagerly looking forward to collaborating with additional consultant oncologists to enhance our expertise further and to enable more people who will benefit from PBT to access it. In closing, I want to express my deepest gratitude to our partners at University College London Hospitals NHS Foundation Trust, the consultants who work with us and my exceptional team at PIL, they have all worked?tirelessly to offer PBT to patients battling different types of cancer. Their commitment to excellence and innovation has been the driving force behind our accomplishments, and I couldn't be prouder of them. To the patients and their families who have entrusted us with their care, we are honoured to be part of your journey towards healing. Here's to a bright and transformative 2024!